{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:28:47Z","timestamp":1786786127387,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-047"],"award-info":[{"award-number":["2022-PUMCH-B-047"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07068-z","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:42:57Z","timestamp":1778870577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"105","author":[{"given":"Jing","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"7068_CR1","doi-asserted-by":"crossref","unstructured":"Susanibar-Adaniya S, Barta SK (2021) Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol 96(5):617\u201329","DOI":"10.1002\/ajh.26151"},{"issue":"3","key":"7068_CR2","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","volume":"6","author":"AE Br\u00f6ske","year":"2022","unstructured":"Br\u00f6ske AE, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR et al (2022) Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma. Blood Adv 6(3):1025\u20131037","journal-title":"Blood Adv"},{"issue":"24","key":"7068_CR3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G et al (2022) Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 387(24):2220\u20132231","journal-title":"N Engl J Med"},{"issue":"4","key":"7068_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN et al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"key":"7068_CR5","doi-asserted-by":"crossref","unstructured":"Brooks TR, Zabor EC, Bedelu Y, Yang XM, Karimi YH, Nedved AN et al (2025) Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood 146(18):2177\u20132188","DOI":"10.1182\/blood.2025029117"},{"issue":"15","key":"7068_CR6","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","volume":"9","author":"E Shumilov","year":"2025","unstructured":"Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U et al (2025) Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study. Blood Adv 9(15):3865\u20133877","journal-title":"Blood Adv"},{"issue":"7","key":"7068_CR7","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1007\/s00277-025-06438-3","volume":"104","author":"R Gurion","year":"2025","unstructured":"Gurion R, Guz D, Kedmi M, Perry C, Avivi I, Horowitz NA et al (2025) Efficacy and safety of Glofitamab in patients with R\/R DLBCL in real life setting- a retrospective study. Ann Hematol 104(7):3821\u20133827","journal-title":"Ann Hematol"},{"issue":"4","key":"7068_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/hon.3174","volume":"41","author":"E Birtas Atesoglu","year":"2023","unstructured":"Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal MS et al (2023) Glofitamab in relapsed\/refractory diffuse large B-cell lymphoma: Real-world data. Hematol Oncol 41(4):663\u2013673","journal-title":"Hematol Oncol"},{"key":"7068_CR9","doi-asserted-by":"crossref","unstructured":"Song YQ, Zhang HL, Huang HQ, Zhang QY, Jing HM, Wang C et al (2024) Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma. Haematologica 109(4):1269\u20131273","DOI":"10.3324\/haematol.2023.283802"},{"issue":"11","key":"7068_CR10","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/cncr.35217","volume":"130","author":"YT Hsu","year":"2024","unstructured":"Hsu YT, Wu SJ, Kao HW, Hsiao SY, Liao CK, Chen TY et al (2024) Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan. Cancer 130(11):1972\u20131981","journal-title":"Cancer"},{"issue":"5","key":"7068_CR11","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857\u20131861","journal-title":"Blood"},{"issue":"11","key":"7068_CR12","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1038\/s41588-025-02353-5","volume":"57","author":"Y Dai","year":"2025","unstructured":"Dai Y, Kizhakeyil A, Chihara D, Li X, Liu Y, Sainz Zuniga TP et al (2025) Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma. Nat Genet 57(11):2715\u20132727","journal-title":"Nat Genet"},{"issue":"22","key":"7068_CR13","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2018889931","volume":"133","author":"M Pascual","year":"2019","unstructured":"Pascual M, Mena-Varas M, Robles EF, Garcia-Barchino MJ, Panizo C, Hervas-Stubbs S et al (2019) PD-1\/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood 133(22):2401\u20132412","journal-title":"Blood"},{"issue":"13","key":"7068_CR14","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","volume":"4","author":"CK Rushton","year":"2020","unstructured":"Rushton CK, Arthur SE, Alcaide M, Cheung M, Jiang A, Coyle KM et al (2020) Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv 4(13):2886\u20132898","journal-title":"Blood Adv"},{"issue":"4","key":"7068_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","volume":"39","author":"M Ghosh","year":"2021","unstructured":"Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T et al (2021) Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell 39(4):494\u2013508e5","journal-title":"Cancer Cell"},{"key":"7068_CR16","doi-asserted-by":"crossref","unstructured":"Blagih J, Buck MD, Vousden KH (2020) p53, cancer and the immune response. J Cell Sci 133(5):jcs237453","DOI":"10.1242\/jcs.237453"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07068-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07068-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07068-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:13Z","timestamp":1786785613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07068-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":16,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["7068"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07068-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"322"}}